Alli is good news for GSK who remain recovering from the basic safety scare over it’s diabetes medication Avandia. GSK hopes the merchandise shall be obtainable in Europe, under a different name, in 2008 and are planning to send Alli for regulatory approval in Canada also, Latin America, China, Australia and New Zealand prior to the last end of 2007. Glaxo is stressing in their advertisements that Alli is normally no magic bullet and requires dedication to a low-fat diet plan. It will contend with multiple OTC health supplements that claim weight-reduction benefits but have not really been cleared by the FDA.. Alli weight loss drug on the U.S. Marketplace soon The new weight loss drug Alli is about to hit the U.S. Marketplace. Alli which is produced by GlaxoSmithKline will be accessible to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.Kaiser Family Foundation. Copyright 2009 Advisory Board Firm and Kaiser Family Base. All rights reserved.. Acceleron’s ACE-031 protein therapeutic for DMD receives FDA Fast Monitor designation Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treating Duchenne Muscular Dystrophy , a fatal neuromuscular disease in which patients have problems with the progressive loss of muscle power and mass.